The estimated Net Worth of Global Strategic Fund, L.P.... is at least $114 millier dollars as of 18 September 2020. Global P owns over 230,000 units of Metacrine stock worth over $113,827 and over the last 4 years Global sold MTCR stock worth over $0.
Global has made over 1 trades of the Metacrine stock since 2020, according to the Form 4 filled with the SEC. Most recently Global bought 230,000 units of MTCR stock worth $2,990,000 on 18 September 2020.
The largest trade Global's ever made was buying 230,000 units of Metacrine stock on 18 September 2020 worth over $2,990,000. On average, Global trades about 230,000 units every 0 days since 2020. As of 18 September 2020 Global still owns at least 230,000 units of Metacrine stock.
You can see the complete history of Global P stock trades at the bottom of the page.
Over the last 4 years, insiders at Metacrine have traded over $5,582,700 worth of Metacrine stock and bought 11,645,167 units worth $119,461,162 . The most active insiders traders include Forest Baskett, Scott D Sandell et Anthony A. Jr. Florence. On average, Metacrine executives and independent directors trade stock every 24 days with the average trade being worth of $237,397. The most recent stock trade was executed by Michael York on 26 January 2023, trading 107,054 units of MTCR stock currently worth $43,892.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine executives and other stock owners filed with the SEC include: